Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
Clinuvel Pharmaceuticals has launched a groundbreaking clinical study, named CUV901, to explore the potential of afamelanotide in treating early-stage Parkinson’s Disease (PD) among fair-skinned individuals. The study intends to assess afamelanotide’s ability to lower toxic α-synuclein levels in the blood and provide neuroprotection by targeting the melanocortin-1 receptor (MC1R), which is often dysfunctional in PD patients. With afamelanotide already used for a different condition in Europe and the USA, this trial represents a significant step toward a novel therapeutic approach for Parkinson’s Disease.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.
